Molecular Genetics of Thyroid Cancer

  • Deanne King
  • Donald Bodenner
  • Brendan C. Stack Jr.
Chapter
First Online:
Part of the Methods of Cancer Diagnosis, Therapy and Prognosis book series (HAYAT, volume 7)

Abstract

Thyroid nodules are exceedingly common and the incidence increases steadily with age. In patients over the age of 50, feeling the neck will detect nodules in 8-10% of patients, and radiology tests such as ultrasound, magnetic resonance imaging (MRI), or computed tomography (CT) will detect nodules in over 50% of individuals over the age of 50. However, it is now clear that only 4-6% of thyroid nodules will be malignant (Belfiore et al. 1992). The incidence of thyroid cancer varies geographically, ranging from 0.5 to 10 cases per 100,000 people (American Cancer Society 2007).

Keywords

Thyroid Cancer Papillary Thyroid Carcinoma Familial Adenomatous Polyposis Thyroid Nodule Adenomatous Polyposis Coli 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

References

  1. Aldred MA, Huang Y, Liyanarachchi S, Pellegata NS, Gimm O, Jhiang S, Davuluri RV, de la Chapelle A, Eng C (2004) Papillary and follicular thyroid carcinomas show distinctly different microarray expression profiles and can be distinguished by a minimum of five genes. J Clin Oncol 22:3531-3539PubMedCrossRefGoogle Scholar
  2. American Cancer Society (2007) Cancer Facts and Figures 2007. http://www.cancer.org/docroot/STT/content/STT_1x_Cancer_Facts__Figures_2007.asp
  3. Belfiore A, La Rosa GL, La Porta GA, Giuffrida D, Milazzo G, Lupo L, Regalbuto C, Vigneri R (1992) Cancer risk in patients with cold thyroid nodules: relevance of iodine intake, sex, age, and multinodularity [see comment]. Am J Med 93:363-369PubMedCrossRefGoogle Scholar
  4. Blagosklonny MV, Giannakakou P, Wojtowicz M, Romanova LY, Ain KB, Bates SE, Fojo T (1998) Effects of p53-expressing adenovirus on the chemosensitivity and differentiation of anaplastic thyroid cancer cells. J Clin Endocrinol Metab 83:2516-2522PubMedCrossRefGoogle Scholar
  5. Bocciardi R, Mograbi B, Pasini B, Borrello MG, Pierotti MA, Bourget I, Fischer S, Romeo G, Rossi B (1997)The multiple endocrine neoplasia type 2B point mutation switches the specificity of the Ret tyrosine kinase towards cellular substrates that are susceptible to interact with Crk and Nck. Oncogene 15:2257-2265Google Scholar
  6. Bolino A, Schuffenecker I, Luo Y, Seri M, Silengo M, Tocco T, Chabrier G, Houdent C, Murat A, Schlumberger M (1995) RET mutations in exons 13 and 14 of FMTC patients. Oncogene 10:2415-2419PubMedGoogle Scholar
  7. Bugalho MJ, Mendonca E, Sobrinho LG (2000) Medullary thyroid carcinoma: an accurate pre-operative diagnosis by reverse transcription-PCR. Eur J Endocrinol 143:335-338PubMedCrossRefGoogle Scholar
  8. Cetta F, Montalto G, Gori M, Curia MC, Cama A, Olschwang S (2000) Germline mutations of the APC gene in patients with familial adenomatous polyposis-associated thyroid carcinoma: results from a European cooperative study. J Clin Endocrinol Metab 85:286-292PubMedCrossRefGoogle Scholar
  9. Cheung CC, Carydis B, Ezzat S, Bedard YC, Asa SL (2001) Analysis of ret/PTC gene rearrangements refines the fine needle aspiration diagnosis of thyroid cancer. J Clin Endocrinol Metab 86:2187-2190PubMedCrossRefGoogle Scholar
  10. Chiappetta G, Toti P, Cetta F, Giuliano A, Pentimalli F, Amendoli I, Lazzi S, Monaco S, Cooper DS, Schneyer CR (1990) Follicular and Hürthle cell carcinoma of the thyroid. Endocrinol Metab Clin N Am 19:577-591Google Scholar
  11. Cooper DS, Schneyer CR (1990) Follicular and Hürthle cell carcinoma of the thyroid. Endocrinol Metab Clin N Am 19:577-591Google Scholar
  12. Corvi R, Lesueur R, Martinez-Alfaro M, Zini M, Decaussin M, Murat A, Romeo G (2001) RET rearrangements in familial papillary thyroid carcinomas. Cancer Lett 170:191-198PubMedCrossRefGoogle Scholar
  13. Duh QY (2005) What’s new in general surgery: endocrine surgery. J Am Coll Surg 201:746-753PubMedCrossRefGoogle Scholar
  14. Eng C, Smith DP, Mulligan LM, Nagai MA, Healey CS, Ponder MA, Gardner E, Scheumann GF, Jackson CE, Tunnacliffe A (1994) Point mutation within the tyrosine kinase domain of the RET proto-oncogene in multiple endocrine neoplasia type 2B and related sporadic tumours. [erratum appears in Hum Mol Genet 1994 Apr; 3(4):686]. Hum Mol Genet 3:237-241Google Scholar
  15. Eng C, Clayton D, Schuffenecker I, Lenoir G, Cote G, Gagel RF, van Amstel HK, Lips CJ, Nishisho I, Takai SI, Marsh DJ, Robinson BG, Frank-Raue K, Raue F, Xue F, Noll WW, Romei C, Pacini F, Fink M, Niederle B, Zedenius J, Nordenskjold M, Komminoth P, Hendy GN, Mulligan LM (1996) The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. JAMA 276:1575-1579PubMedCrossRefGoogle Scholar
  16. Fagin JA (2002) Perspective: lessons learned from molecular genetic studies of thyroid cancer - insights into pathogenesis and tumor-specific therapeutic targets. Endocrinology 143:2025-2028PubMedCrossRefGoogle Scholar
  17. Fattoruso O, Quadro L, Libroia A, Verga U, Lupoli G, Cascone E, Colantuoni V (1998) A GTG to ATG novel point mutation at codon 804 in exon 14 of the RET proto-oncogene in two families affected by familial medullary thyroid carcinoma. Hum Mut Suppl 1:S167-S171CrossRefGoogle Scholar
  18. Finley DJ, Zhu B, Fahey TJ III (2004a) Molecular analysis of Hürthle cell neoplasms by gene profiling. Surgery 136:1160-1168PubMedCrossRefGoogle Scholar
  19. Finley DJ, Arora N, Zhu B, Gallagher L, Fahey TJ 3rd (2004b) Molecular profiling distinguishes papillary carcinoma from benign thyroid nodules. J Clin Endocrinol Metab 89:3214-3223PubMedCrossRefGoogle Scholar
  20. Finley DJ, Zhu B, Barden CB, Fahey TJ 3rd (2004c) Discrimination of benign and malignant thyroid nodules by molecular profiling. Ann Surg 240:425-437PubMedCrossRefGoogle Scholar
  21. Gimm O, Marsh DJ, Andrew SD, Frilling A, Dahia PL, Mulligan LM, Zajac JD, Robinson BG, Eng C (1997) Germline dinucleotide mutation in codon 883 of the RET proto-oncogene in multiple endocrine neoplasia type 2B without codon 918 mutation. J Clin Endocrinol Metab 82:3902-3904PubMedCrossRefGoogle Scholar
  22. Haugen BR, Woodmansee WW, McDermott MT (2002) Towards improving the utility of fine-needle aspiration biopsy for the diagnosis of thyroid tumours. Clin Endocrinol 56:281-290CrossRefGoogle Scholar
  23. Hofstra RM, Landsvater RM, Ceccherini I, Stulp RP, Stelwagen T, Luo Y, Pasini B, Hoppener JW, van Amstel HK, Romeo G (1994) A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma. [See comments]. Nature 367:375-376PubMedCrossRefGoogle Scholar
  24. Hofstra RM, Fattoruso O, Quadro L, Wu Y, Libroia A, Verga U, Colantuoni V, Buys CH (1997) A novel point mutation in the intracellular domain of the ret protooncogene in a family with medullary thyroid carcinoma. J Clin Endocrinol Metab 82:4176-4178PubMedCrossRefGoogle Scholar
  25. Horie H, Yokogashi Y, Tsuyuguchi M, Saito S (1995) Point mutations of ras and Gs alpha subunit genes in thyroid tumors. Jpn J Cancer Res 86:737-742PubMedCrossRefGoogle Scholar
  26. Lacroix L, Mian C, Barrier T, Talbot M, Caillou B, Schlumberger M, Bidart JM (2004) PAX8 and peroxisome proliferator-activated receptor gamma 1 gene expression status in benign and malignant thyroid tissues. Eur J Endocrinol 151:367-374PubMedCrossRefGoogle Scholar
  27. Learoyd DL, Messina M, Zedenius J, Robinson BG (2000) Molecular genetics of thyroid tumors and surgical decision-making. World J Surg 24:923-933PubMedCrossRefGoogle Scholar
  28. Lo CY, Lam KY, Wan KY (1999) Anaplastic carcinoma of the thyroid. Am J Surg 177:337-339PubMedCrossRefGoogle Scholar
  29. Malchoff CD, Malchoff DM (2002) The genetics of hereditary nonmedullary thyroid carcinoma. J Clin Endocr Metab 87:2455-2459PubMedCrossRefGoogle Scholar
  30. Marchesi M, Biffoni M, Cresti R, Mariotti F, Mulas M (2000) Familial papillary carcinoma of the thyroid: a report of nine first-degree relatives of four families. Eur J Surg Oncol 26:789-791PubMedCrossRefGoogle Scholar
  31. Mathew CG, Chin KS, Easton DF, Thorpe K, Carter C, Liou GI, Fong SL, Bridges CD, Haak H, Kruseman AC (1987) A linked genetic marker for multiple endocrine neoplasia type 2A on chromosome 10. Nature 328:527-528PubMedCrossRefGoogle Scholar
  32. Mazzanti C, Zeiger MA, Costouros NG, Umbricht C, Westra WH, Smith D, Somervell H, Bevilacqua G, Alexander HR, Libutti SK (2004) Using gene expression profiling to differentiate benign versus malignant thyroid tumors. Cancer Res 64:2898-2903PubMedCrossRefGoogle Scholar
  33. McDonald MP, Zhao G, Stringer JR, Medvedovic M, Moretti S, Fagin JA (1996) Hürthle cell carcinoma of the thyroid gland: prognostic factors and results of surgical treatment. Surgery 120:1000-1004, discussion 1004-1005Google Scholar
  34. Moretti F, Farsetti A, Soddu S, Misiti S, Crescenzi M, Filetti S, Andreoli M, Sacchi A, Pontecorvi A (1997) p53 re-expression inhibits proliferation and restores differentiation of human thyroid anaplastic carcinoma cells. Oncogene 14:729-740PubMedCrossRefGoogle Scholar
  35. Mulligan LM, Marsh DJ, Robinson BG, Schuffenecker I, Zedenius J, Lips CJ, Gagel RF, Takai SI, Noll WW, Fink M (1995) Genotype-phenotype correlation in multiple endocrine neoplasia type 2: report of the international RET mutation consortium. J Int Med 238:343-346CrossRefGoogle Scholar
  36. Musholt TJ, Musholt PB, Petrich T, Oetting G, Knapp WH, Klempnauer J (2000) Familial papillary thyroid carcinoma: genetics, criteria for diagnosis, clinical features, and surgical treatment. World J Surg 24:1409-1417PubMedCrossRefGoogle Scholar
  37. Nagayama Y, Yokoi H, Takeda K, Hasegawa M, Nishihara E, Namba H, Yamashita S, Niwa M (2000) Adenovirus-mediated tumor suppressor p53 gene therapy for anaplastic thyroid carcinoma in vitro and in vivo. J Clin Endocrinol Metab 85:4081-4086PubMedCrossRefGoogle Scholar
  38. Namba H, Rubin SA, Fagin JA (1990) Point mutations of ras oncogenes are an early event in thyroid tumorigenesis. Mol Endocrinol 4:1474-1479PubMedCrossRefGoogle Scholar
  39. Nikiforova MN, Lynch RA, Biddinger PW, Alexander EK, Dorn GW 2nd, Tallini G, Kroll TG, Nikiforov YE (2003) RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma. J Clin Endocrinol Metab 88:2318-2326PubMedCrossRefGoogle Scholar
  40. O’Neill JP, Condron C, Walsh M, Bouchier-Hayes D (2005) Anaplastic (undifferentiated) thyroid cancer: improved insight and therapeutic strategy into a highly aggressive disease. J Laryngol Otol 119:585-591PubMedGoogle Scholar
  41. Puxeddu E, Moretti S, Giannico A, Martinelli M, Mariano C, Avenia N, Cristofani R, Farabi R, Reboldi G, Ribacchi R, Pontecorvi A, Santeusanio F (2003) Ret/PTC activation does not influence clinical and pathological features of adult papillary thyroid carcinomas. Eur J Endocrinol 148:505-513PubMedCrossRefGoogle Scholar
  42. Puxeddu E, Moretti S, Elisei R, Romei C, Pascucci R, Martinelli M, Marino C, Avenia N, Rossi ED, Fadda G, Cavaliere A, Ribacchi R, Falorni A, Pontecorvi A, Pacini F, Pinchera A, Santeusanio F (2004) BRAF(V599E) Mutation is the leading genetic event in adult sporadic papillary thyroid carcinomas. J Clin Endocrinol Metab 89:2414-2420PubMedCrossRefGoogle Scholar
  43. Puxeddu E, Zhao G, Stringer JR, Medvedovic M, Moretti S, Fagin JA (2005) Characterization of novel non-clonal intrachromosomal rearrangements between the H4 and PTEN genes (H4/PTEN) in human thyroid cell lines and papillary thyroid cancer specimens. Mut Res/Fund Mol Mech Mutagen 570:17-32CrossRefGoogle Scholar
  44. Samaan NA, Schultz DN, Ordonez NG, Hickey RC, Johnston DA (1987) A comparison of thyroid carcinoma in those who have and have not had head and neck cancer irradiation in childhood. J Clin Endocrinol Metab 64:214-223CrossRefGoogle Scholar
  45. Soravia C, Sugg SL, Berk T, Mitri A, Cheng H, Gallinger S, Cohen Z, Asa SL, Bapat BV (1999) Familial adenomatous polyposis-associated thyroid cancer: a clinical, pathological, and molecular genetics study. Am J Path 154:127-135PubMedCrossRefGoogle Scholar
  46. Suarez HG, Du Villard JA, Caillou B, Schlumberger M, Tubiana M, Parmentier C, Monier R (1988) Detection of activated ras oncogenes in human thyroid carcinomas. Oncogene 2:403-406PubMedGoogle Scholar
  47. Sugawara I, Arai T, Yamashita T, Yoshida A, Masunaga A, Itoyama S (1994) Expression of multidrug resistance-associated protein (MRP) in anaplastic carcinoma of the thyroid. Cancer Lett 82:185-188PubMedCrossRefGoogle Scholar
  48. Sugg SL, Ezzat S, Rosen IB, Freeman JL, Asa SL (1998) Distinct multiple RET/PTC gene rearrangements in multifocal papillary thyroid neoplasia. J Clin Endocrinol Metab 83:4116-4122PubMedCrossRefGoogle Scholar
  49. Tucker MA, Jones PH, Boice JD Jr, Robinson LL, Stone BJ, Stovall M, Jenkin RD, Lubin JH, Baum ES, Siegel SE (1991) Therapeutic radiation at a young age is linked to secondary thyroid cancer. The late effects study group. Cancer Res 51:2885-2888PubMedGoogle Scholar
  50. Utiger RD (2005) The multiplicity of thyroid nodules and carcinomas. [comment]. N Eng J Med 352:2376-2378CrossRefGoogle Scholar
  51. Weber F, Shen L, Aldred MA, Morrison CD, Frilling A, Saji M, Schuppert F, Broelsch CE, Ringel MD, Eng C (2005) Genetic classification of benign and malignant thyroid follicular neoplasia based on a three-gene combination. J Clin Endocrinol Metabol 90:2512-2521CrossRefGoogle Scholar
  52. Xing M, Tufano RP, Tufano AP, Basaria S, Ewertz M, Rosenbaum E, Byrne PJ, Wang J, Sidransky D, Ladenson PW (2004) Detection of BRAF mutation on fine needle aspiration biopsy specimens: a new diagnostic tool for papillary thyroid cancer. J Clin Endocrinol Metab 89:2867-2872PubMedCrossRefGoogle Scholar
  53. Zeiger MA, Smallridge RC, Clark DP, Liang CK, Carty SE, Watson CG, Udelsman R, Saji M (1999) Human telomerase reverse transcriptase (hTERT) gene expression in FNA samples from thyroid neoplasms. Surgery 126:1195-1198PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2010

Authors and Affiliations

  • Deanne King
    • 1
  • Donald Bodenner
    • 2
  • Brendan C. Stack Jr.
    • 3
  1. 1.Department of Otolaryngology-Head and Neck SurgeryThyroid Clinic, Arkansas Cancer Research Center, University of Arkansas for Medical SciencesLittle RockUSA
  2. 2.Division of Geriatric Endocrinology, Department of GeriatricsUniversity of Arkansas for Medical SciencesLittle RockUSA
  3. 3.Department Otolaryngology-Head and Neck SurgeryUniversity of Arkansas for Medical SciencesLittle RockUSA

Personalised recommendations